Skip to content


Open Access

Development of a Quantum Dot-based Assay System for Detection of Specific HIV-1 LTR Sequence Variants

  • Asiedua Asante1,
  • Michael Nonnemacher1,
  • Aikaterini Alexaki1,
  • Elisabeth Papazoglou2,
  • Peter Lelkes2 and
  • Brian Wigdahl1
Retrovirology20052(Suppl 1):P9

Published: 8 December 2005


Human Immunodeficiency VirusDementiaLong Terminal RepeatTranscription Factor BindingTranscription Factor Binding Site

Analysis of human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) sequence variation within the CCAAT/enhancer binding protein (C/EBP) and stimulating protein (Sp) transcription factor binding sites has identified variants that correlate with HIV-associated dementia (HIVD). CdSe/ZnS nanocrytsals have facilitated the investigation of nano- and peco-scale biological components. Quantum dot-conjugated oligonucleotides homologous to specific variants of Sp site III and C/EBP site I, were utilized to quantitate the relative abundance of specific LTR variants. Quantum dot-conjugated oligonucleotides containing the Sp site III 5T binding site variant (C-to-T change at position 5) or the C/EBP site I 3T site variant, were reacted with plasmid DNA containing increasing concentrations of plasmid with the homologous LTR sequence variant. The results suggest that quantum dot-conjugated oligonucleotides specific for sequence variants within the LTR can be used as reporter molecules for identification and quantitation of HIV-1 genetic variation.


Authors’ Affiliations

Department of Microbiology and Immunology and Institute for Molecular Medicine and Infectious Disease, Philadelphia, USA
School of Biomedical Engineering, Science, and Health Systems, Drexel University College of Medicine, Philadelphia, USA


© The Author(s) 2005